Century Therapeutics, Inc. (NASDAQ:IPSC) Receives $10.00 Average PT from Analysts

Shares of Century Therapeutics, Inc. (NASDAQ:IPSC) have been assigned a consensus rating of “Buy” from the six research firms that are currently covering the stock, Marketbeat.com reports. Six equities research analysts have rated the stock with a buy rating. The average 12 month target price among brokerages that have covered the stock in the last year is $10.00.

A number of equities analysts have issued reports on IPSC shares. Guggenheim reaffirmed a “buy” rating on shares of Century Therapeutics in a research note on Wednesday, January 22nd. Piper Sandler reduced their price objective on shares of Century Therapeutics from $12.00 to $4.00 and set an “overweight” rating on the stock in a research note on Monday, December 30th. HC Wainwright reaffirmed a “buy” rating and issued a $5.00 price objective on shares of Century Therapeutics in a research note on Wednesday, January 22nd. Finally, Chardan Capital cut their target price on shares of Century Therapeutics from $17.00 to $11.00 and set a “buy” rating on the stock in a report on Thursday, November 7th.

Institutional Investors Weigh In On Century Therapeutics

Several hedge funds have recently bought and sold shares of the company. Renaissance Technologies LLC raised its holdings in shares of Century Therapeutics by 6.1% during the second quarter. Renaissance Technologies LLC now owns 165,500 shares of the company’s stock worth $422,000 after acquiring an additional 9,500 shares during the period. SG Americas Securities LLC acquired a new stake in shares of Century Therapeutics during the third quarter worth $27,000. Rhumbline Advisers raised its holdings in shares of Century Therapeutics by 56.0% during the second quarter. Rhumbline Advisers now owns 52,466 shares of the company’s stock worth $134,000 after acquiring an additional 18,828 shares during the period. Geode Capital Management LLC raised its holdings in shares of Century Therapeutics by 3.5% during the third quarter. Geode Capital Management LLC now owns 968,182 shares of the company’s stock worth $1,656,000 after acquiring an additional 32,614 shares during the period. Finally, Dimensional Fund Advisors LP raised its holdings in shares of Century Therapeutics by 141.7% during the second quarter. Dimensional Fund Advisors LP now owns 75,315 shares of the company’s stock worth $192,000 after acquiring an additional 44,155 shares during the period. 50.20% of the stock is currently owned by institutional investors and hedge funds.

Century Therapeutics Price Performance

IPSC opened at $0.85 on Wednesday. Century Therapeutics has a one year low of $0.83 and a one year high of $5.51. The company’s 50 day simple moving average is $1.15 and its 200-day simple moving average is $1.51. The stock has a market capitalization of $71.85 million, a P/E ratio of -0.46 and a beta of 1.76.

Century Therapeutics (NASDAQ:IPSC) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.08. Century Therapeutics had a negative net margin of 4,837.73% and a negative return on equity of 61.66%. The firm had revenue of $0.79 million for the quarter, compared to analysts’ expectations of $0.47 million. During the same period last year, the firm earned ($0.55) earnings per share. As a group, analysts anticipate that Century Therapeutics will post -1.63 EPS for the current year.

About Century Therapeutics

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.